Use of antiarrhythmic compounds for reducing post-infarction mortality
CA 2249481 A1 · Owner: Sanofi-Synthelabo · Inventors: Munoz, Alain; Frangin, Gerald
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The use of benzofuran derivatives having antiarrhythmic activity particularly amiodarone or dronedarone or a pharmaceutically acceptable salt thereof for preparing pharmaceutical compositions capable of reducing cardiac-related mortality particularly arrhythmia-related mortality and sudden death in patients who have a reduced left ventricular function following a myocardial infarction but do not have a disturbed cardiac rhythm requiring an antiarrhythmic treatment is disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 17, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 17, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 17, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.